Overcoming purification challenges in antibody therapeutics manufacturing with subdomain-specific affinity solutions

Published: 8 September 2021
Innovator Insight
Laurens Sierkstra
Laurens Sierkstra
Senior Director, Business Leader Purification, Thermo Fisher Scientific
Laurens received his PhD in biotechnology in 1994 from the University of Utrecht after studying biology at the University of Leiden. He then joined Unilever as Project Manager and Unit Leader. In 2005, after the spinout of BAC BV from Unilever, he became CEO of BAC BV and set up the business in using single- domain antibodies for affinity purification, called CaptureSelect, which was sold in 2013 to Life Technologies. Since the acquisition by Thermo Fisher Scientific, he has been the business leader for the affinity purification business within the Bioproduction Division.

Novel biotherapeutic antibody formats, such as bispecific monoclonal antibodies, Fab fragments, and Fc-fusion proteins have created new purification challenges in downstream processing. The use of bacterial surface proteins, such as Protein A, is not always the most efficient solution for the purification of these novel modalities. Affinity chromatography resins, specifically developed to bind antibody subdomain regions, can provide an alternative solution for a variety of antibody formats.

Please note all fields marked with an * are mandatory

View article

Already registered? Login

If you have any problem accessing our content, please email info@insights.bio